Business Wire

NTHU

Share
Joint Tsinghua-Liverpool Research Team Discover New Charge Storage Mechanism

Due to their high energy density and low cost, metal-air batteries are one of the most promising power sources of the future. A joint Tsinghua-Liverpool research team has recently developed a new charge storage mechanism that allows rechargeability within calcium-air batteries - a major step forward in battery technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210816005031/en/

This discovery has been published in Chemical Science . The lead author of the paper, Yi-Ting Lu, is a joint doctoral student at Tsinghua and Liverpool, whose supervisors are Prof. Chi-Chang Hu (Department of Chemical Engineering, NTHU) and Prof. Laurence Hardwick (Department of Chemistry, UoL).

A major breakthrough related to Ca-air batteries

Prof. Hu said conventional lithium-ion batteries have a limited practical capacity. Thereby many researchers are working on developing alternative battery technologies. Their focus is on metal-air batteries based on zinc, lithium, sodium, potassium, calcium, magnesium, and aluminum. The advantage of the calcium-air battery is its high specific energy—five times that of traditional lithium-ion batteries. However, the feasibility of calcium-air batteries remains hampered by one major drawback—it cannot be recharged.

Lu explained that metal-air batteries are electrochemical cells usually using an active metal as the negative electrode, and a porous carbon material in contact with the air as the positive electrode. When the metal oxidized the oxygen at the positive electrode is reduced, generating electric current.

After completing his first year of doctoral studies at NTHU, Lu enrolled at the Stephenson Institute for Renewable Energy at UoL in September 2018. Under the supervision of Prof. Hardwick, he began doing research on the electrolyte used in calcium-air batteries.

Lu found when a single electrode is repeatedly charged and discharged, initially no reversibility can be observed, but after a few dozen cycles it gradually displays some reversibility. Surprisingly, the result seemed completely different from those in literature. The research team conducted a series of experiments aimed at uncovering the mechanism behind this phenomenon. On the electrode surface, the discharge products form a calcium oxide (Cax Oy ) interlayer, where the discharge product of oxygen, known as superoxide, is confined, allowing the superoxide to be then readily oxidized. This suggests the oxygen could probably be repeatedly oxidized/reduced, so that the cell can be continuously discharged/recharged.

Dr. Alex Neale, a Liverpool postdoctoral researcher, who is also part of the research team, said that through systematic electrochemical and spectroscopy investigations, the team began to understand the origins of this charge storage mechanism that facilitates a previously unseen degree of reversibility for systems based on the calcium-air battery.

Prof. Hardwick said the team will focus on designing new battery systems that use this newly discovered charge storage mechanism. He added that it was the cooperative research that made their discovery possible, and there are plans for even closer cooperation between NTHU and UoL in the future.

Social Media:

https://www.facebook.com/nthu.tw

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye